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1. Introduction {#jia225200-sec-0005}
===============

World Health Organization (WHO) guidelines on initiating combination antiretroviral therapy (cART) in children have expanded paediatric cART eligibility. The initial WHO guidelines (2002, revised in 2006) established CD4 thresholds for cART initiation across all paediatric age groups [1](#jia225200-bib-0001){ref-type="ref"}. In 2010, immediate cART initiation regardless of immunological or clinical thresholds was recommended for children aged \<2 years [2](#jia225200-bib-0002){ref-type="ref"} and expanded in 2013 to all children \<5 years [3](#jia225200-bib-0003){ref-type="ref"} and in 2016 to all adults and children living with HIV [4](#jia225200-bib-0004){ref-type="ref"}. These modifications were largely predicated by the rapid HIV disease progression and high morbidity and mortality in infants and children [5](#jia225200-bib-0005){ref-type="ref"}, [6](#jia225200-bib-0006){ref-type="ref"}, [7](#jia225200-bib-0007){ref-type="ref"}, together with evidence of lower mortality (particularly in infants \<3 months of age) [8](#jia225200-bib-0008){ref-type="ref"} as well as better growth, immunological and morbidity outcomes and less chronic organ system disease associated with early cART initiation [9](#jia225200-bib-0009){ref-type="ref"}, [10](#jia225200-bib-0010){ref-type="ref"}, [11](#jia225200-bib-0011){ref-type="ref"}, [12](#jia225200-bib-0012){ref-type="ref"}, [13](#jia225200-bib-0013){ref-type="ref"}, [14](#jia225200-bib-0014){ref-type="ref"}, [15](#jia225200-bib-0015){ref-type="ref"}, [16](#jia225200-bib-0016){ref-type="ref"}, [17](#jia225200-bib-0017){ref-type="ref"}, [18](#jia225200-bib-0018){ref-type="ref"}, [19](#jia225200-bib-0019){ref-type="ref"}. An additional motivation for recommending earlier cART in children was to address the lag in paediatric cART coverage [20](#jia225200-bib-0020){ref-type="ref"}.

Serial monitoring of CD4 at cART initiation is important for programme evaluation, indicating the extent to which guideline changes are successfully implemented so that children initiate cART before onset of advanced HIV disease. An analysis from sub‐Saharan Africa, Asia, North America and Latin America from 2004 to 2010 demonstrated reductions in the proportions of children initiating cART with severe immunodeficiency, but even in 2010 the vast majority of children in low‐ and middle‐income countries continued to start cART late [21](#jia225200-bib-0021){ref-type="ref"}. The ongoing high burden of advanced HIV disease was a key motivation for the recent WHO 2017 guidelines on managing advanced disease [22](#jia225200-bib-0022){ref-type="ref"}. We analysed CD4 measures at cART initiation from an international collaboration of treatment programmes in sub‐Saharan Africa, Asia, Europe, Central and South America, and North America from 1996 to 2013 in order to assess changes in the proportion of children starting cART with advanced HIV disease and the impact of WHO treatment initiation guidelines on this proportion.

2. Methods {#jia225200-sec-0006}
==========

2.1. Data sources {#jia225200-sec-0007}
-----------------

Data were collated from four major cohort research networks: the International Epidemiology Databases to Evaluate AIDS (IeDEA); the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); the Adolescent Master Protocol (AMP) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network; and the 219C Long‐Term Follow‐Up Study of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network. IeDEA is a global consortium with regional centres that pool clinical and epidemiological data on individuals living with HIV; regions collecting paediatric data are Caribbean/Central and South America, Asia‐Pacific, East Africa, West Africa, Central Africa and Southern Africa [23](#jia225200-bib-0023){ref-type="ref"}. COHERE is a collaboration of European HIV cohorts that conducts epidemiological research on the prognosis of people living with HIV across Europe [24](#jia225200-bib-0024){ref-type="ref"}. IMPAACT 219C and PHACS AMP are US‐based prospective cohort studies designed to evaluate the impact of HIV infection and cART on youth. New enrolment in recent years is limited [25](#jia225200-bib-0025){ref-type="ref"}, [26](#jia225200-bib-0026){ref-type="ref"}, [27](#jia225200-bib-0027){ref-type="ref"}. Pooling of data and their use in collaborative analyses were approved by local institutional review boards. For the present study, regional centres sent de‐identified data to the University of Bern, Switzerland, for cleaning and analysis.

2.2. Inclusion criteria and definitions {#jia225200-sec-0008}
---------------------------------------

All patients living with HIV aged \<16 years at cART start (irrespective of likely mode of infection) were included in descriptive analyses if they had documented sex and cART start date after 1994, were treatment‐naïve at cohort entry (except for exposure to antiretrovirals for prevention of mother‐to‐child transmission (PMTCT)) or had CD4 measured at first cART start if not naïve at cohort entry. For further analyses, we excluded data from low‐ or middle‐income countries before widespread cART rollout began in 2002 and from countries that contributed \<50 patients with a CD4 measurement at cART start. We also excluded data on children who started therapy in a year and country for which \<10 children with CD4 measures were reported as well as data from the last calendar year in countries where no CD4 measures were available after May of that calendar year. cART was typically defined by participating cohorts as a regimen of ≥3 antiretroviral drugs from ≥2 drug classes. The baseline CD4 value was defined as the value nearest the cART start date within −6 to +1 months of start. Countries were grouped according to the World Bank classification of annual Gross National Income per capita 2013 as low‐income (LIC, ≤US\$1045), lower middle‐income (LMIC, US\$1046‐4125), upper middle‐income (UMIC, US\$4126 to 12,745) and high‐income (HIC, ≥US\$12,746). We used the 2013 classification as this was the most recent year for which data was included [28](#jia225200-bib-0028){ref-type="ref"}. Age groups at cART initiation were less than twelve months, twelve to thirty‐five months, thirty‐six to fifty‐nine months, five to eleven years and twelve to fifteen years. Severe immunodeficiency was defined according to WHO as CD4% \<25% (age \<12 months), \<20% (12 to 35 months), \<15% (36 to 59 months) and CD4 count \<200 cells/μL or CD4% \<15% (≥5 years) [29](#jia225200-bib-0029){ref-type="ref"}.

2.3. Multiple imputation of missing CD4 measurements {#jia225200-sec-0009}
----------------------------------------------------

We imputed missing CD4 measures at cART initiation from 1996 (HIC) and 2002 (LIC, LMIC and UMIC) onwards for countries and calendar years. We imputed the arcsine square root of CD4% and square root of CD4 cell count simultaneously using chained equations and predictive mean matching, adjusting for country and year of cART start, stratifying by sex, age, income group and cohort. We generated 50 imputed data sets and combined these using Rubin\'s rule [30](#jia225200-bib-0030){ref-type="ref"}.

2.4. Analysis of temporal trends in CD4 measurements {#jia225200-sec-0010}
----------------------------------------------------

We used generalized additive mixed models to analyse temporal trends in CD4 measures by sex, age and country income group. We assessed three key outcomes at cART initiation: the proportion of children with severe immunodeficiency; median CD4% (aged \<5 years); and median CD4 count (aged ≥5 years). Sex, age group and income group and their interactions were entered as fixed effects and country as a random intercept. Yearly trends were smoothed by sex, age group and income group. Data were aggregated by calendar year (three to sixteen years, depending on country), country (thirty‐two countries), sex and age group prior to analysis: each combination of these factors corresponded to a cell in the analysis. For each cell, we calculated the number of children with severe immunodeficiency and the median CD4% and count. Each cell was entered in the model with a two‐part weight. The first part incorporated the precision of the aggregated values for each cell into the model and corresponded to the number of observations contained in a cell, divided by the average number of observations in all cells in the same income group. The second part corresponded to the ratio of the number of patients that were newly enrolled in that cohort for that year and the number of patients that started cART in that country during that year [31](#jia225200-bib-0031){ref-type="ref"}. The weights of the second part were also normalized by country income group. We used the data set with imputed data for the main analysis. In sensitivity analyses, we fitted the model restricted to the subset with complete data.

2.5. Influence of WHO guidelines on the proportion starting cART with advanced disease {#jia225200-sec-0011}
--------------------------------------------------------------------------------------

From 2002 to 2013, there were two major changes in WHO paediatric cART initiation guidelines. Before 2006, WHO guidelines for initiation of cART in children were included in the adult guidelines; children were cART eligible with WHO Stage 3 disease (AIDS; note Stage 4 disease not defined at that time) or Stage 2 disease if CD4% \<20% (age \<18 months) or \<15% (age \>18 months) [32](#jia225200-bib-0032){ref-type="ref"}. In 2006, WHO released revised stand‐alone guidelines for children, based on a public health approach [1](#jia225200-bib-0001){ref-type="ref"}. In the 2006 guidelines, WHO cART eligibility criteria were: WHO Clinical Stages 3/4, CD4 \< 1500 cells/μL or 25% (age \<12 months), CD4 \< 750 cells/μL or 20% (12 to 35 months), CD4 \< 350 cells/μL or 15% (36 to 59 months) and CD4 ≤ 200 cells/μL (≥5 years) [1](#jia225200-bib-0001){ref-type="ref"}. In 2010, WHO recommended cART regardless of immunologic or clinical thresholds for children \<2 years, children with WHO Clinical Stages 3/4, CD4 \< 750 cells/μL or 25% (age two to five years) and CD4 ≤ 350 cells/μL (age ≥5 years) [2](#jia225200-bib-0002){ref-type="ref"}. We performed segmented (piecewise) linear regression to test whether the guideline changes affected the speed of decline in the proportion of children with severe immunodeficiency at cART initiation. Segments were calendar periods 2002 to 2005, 2006 to 2009 and 2010 to 2013, assuming change points at 2006 and 2010 [1](#jia225200-bib-0001){ref-type="ref"}, [2](#jia225200-bib-0002){ref-type="ref"}. We used a generalized linear mixed effects model with income groups as fixed effects and countries as random effects. The main slope was the middle period (2006 to 2009). The variability in the country effect was expressed by a different intercept, allowing parallel deviations from the average income group and random slopes, accounting for slower or faster than average decreases. The model allowed different slopes for different periods but forced the line segments for the three periods to be continuous at the change points, and the change in slopes between periods to be the same for all countries within each income group. We estimated confidence intervals (CI) to determine whether slopes in 2002 to 2005 and 2010 to 2013 differed from the reference slope (2006 to 2009).

The technical appendix provides further details on the multiple imputation and smoothing (see Appendix 1). Analyses were conducted in R 3.1.0 (R Core Team, Vienna, Austria).

3. Results {#jia225200-sec-0012}
==========

3.1. Descriptive analyses {#jia225200-sec-0013}
-------------------------

Data from 67,486 children from 44 countries \<16 years old at cART start were submitted to the data centre (Figure [S1](#jia225200-sup-0001){ref-type="supplementary-material"}). We excluded 13,383 participants who did not meet the inclusion criteria, mostly because they were not treatment‐naïve at cohort entry; hence, 54,103 children from 41 countries were included in descriptive analyses (Figure [1](#jia225200-fig-0001){ref-type="fig"}). We excluded 1950 children from further analyses using multiple imputation (nine countries) either because their CD4 measures were before 1996 (HIC) or 2002 (LIC, LMIC and UMIC) (268 children), or from calendar years with \<10 children in that country with CD4 measures (1544 children) or with no measure after May of the last calendar year for the relevant country (138 children) (Figure [S1](#jia225200-sup-0001){ref-type="supplementary-material"}). Data typically spanned the years 2003 to 2013 in low‐ and middle‐income countries and 1997 to 2012 in HIC; in the USA, data were only available for 1996 to 2006, as all participants initiated cART before 2007 (Table [1](#jia225200-tbl-0001){ref-type="table"}). The median year of cART initiation ranged from 1998 in the US to 2012 in Mozambique. The median (interquartile range (IQR)) age of children starting cART was 6 years (3 to 10) in LIC, 5 (2 to 10) in LMIC, 6 (2 to 10) in UMIC and 6 (2 to 10) in HIC. Median CD4 cell counts/percentages at cART initiation by country and sex are shown in Table [2](#jia225200-tbl-0002){ref-type="table"}. The median CD4 count at cART start for children ≥5 years old was 250 cells/μL (106 to 416) in LIC, 258 (118 to 446) (LMIC), 189 (57 to 349) (UMIC) and 348 (179 to 601) (HIC). Similar patterns were evident for CD4% in children \<5 years (Table [2](#jia225200-tbl-0002){ref-type="table"}). The overall percentage (95%CI) of children starting cART with severe immunodeficiency was 48% (47% to 49%) (LIC), 52% (51% to 53%) (LMIC), 57% (56% to 58%) (UMIC) and 31% (30% to 33%) (HIC).

![**Map of countries contributing patients to the collaborative analysis**](JIA2-21-e25200-g001){#jia225200-fig-0001}

###### 

Characteristics at cART initiation of 54,103 children starting cART by country income group

  Country               Number of patients   Median age in years   Median calendar year of starting cART   Calendar year range of data   Calendar year range of data used in analysis                                        
  --------------------- -------------------- --------------------- --------------------------------------- ----------------------------- ---------------------------------------------- --------------------- -------------- --------------
  Low‐income                                                                                                                                                                                                                 
  Benin                 103                  120                   4                                       4                             2008                                           2009                  2002 to 2012   2004 to 2011
  Burkina Faso          196                  176                   7                                       6                             2008                                           2009                  2001 to 2012   2003 to 2012
  Cambodia              191                  196                   6                                       6                             2007                                           2007                  2004 to 2012   2005 to 2010
  Congo, DR             529                  524                   6                                       6                             2009                                           2009                  2004 to 2013   2004 to 2013
  Haiti                 373                  314                   6                                       7                             2009                                           2008                  2003 to 2013   2003 to 2012
  Kenya                 4227                 4199                  6                                       6                             2010                                           2010                  2002 to 2012   2003 to 2012
  Malawi                2113                 2072                  6                                       6                             2009                                           2009                  2000 to 2013   2005 to 2010
  Mali                  465                  659                   4                                       4                             2007                                           2007                  2001 to 2012   2002 to 2012
  Mozambique            217                  224                   2                                       2                             2012                                           2012                  2005 to 2014   2007 to 2013
  Rwanda                506                  497                   9                                       8                             2008                                           2008                  2000 to 2013   2004 to 2013
  Tanzania, UR          398                  378                   7                                       6                             2009                                           2009                  2005 to 2013   2005 to 2012
  Togo                  155                  154                   4                                       4                             2011                                           2011                  2005 to 2012   2010 to 2012
  Uganda                239                  252                   4                                       5                             2010                                           2010                  2002 to 2012   2006 to 2011
  Zimbabwe              1535                 1537                  9                                       9                             2011                                           2011                  1999 to 2014   2005 to 2013
  Overall (IQR)         11,247               11,302                6 (3 to 11)                             6 (3 to 10)                   2010 (2007 to 2011)                            2009 (2007 to 2011)   1999 to 2014   2002 to 2013
  Lower middle‐income                                                                                                                                                                                                        
  Cameroon              4                    1                     12                                      15                            2006                                           2007                  2003 to 2008   Excluded
  Cote d\'Ivoire        973                  1030                  6                                       6                             2007                                           2007                  2001 to 2012   2004 to 2012
  Ghana                 249                  276                   6                                       5                             2008                                           2009                  2001 to 2012   2004 to 2012
  Honduras              16                   13                    3                                       5                             2005                                           2005                  2002 to 2009   Excluded
  India                 49                   68                    9                                       8                             2008                                           2008                  2001 to 2012   2005 to 2010
  Indonesia             103                  111                   3                                       2                             2009                                           2008                  2005 to 2013   2005 to 2012
  Lesotho               355                  381                   6                                       6                             2011                                           2010                  2003 to 2014   2006 to 2013
  Senegal               150                  196                   6                                       5                             2009                                           2008                  2000 to 2012   2005 to 2011
  Vietnam               493                  621                   4                                       4                             2009                                           2009                  2005 to 2013   2005 to 2012
  Zambia                7315                 7090                  6                                       5                             2009                                           2009                  2003 to 2011   2004 to 2011
  Overall (IQR)         9707                 9787                  6 (2 to 10)                             5 (2 to 9)                    2009 (2007 to 2010)                            2009 (2007 to 2010)   2000 to 2014   2004 to 2013
  Upper middle‐income                                                                                                                                                                                                        
  Argentina             5                    5                     7                                       6                             2002                                           2009                  2001 to 2010   Excluded
  Brazil                212                  200                   4                                       5                             2003                                           2003                  1997 to 2012   2002 to 2012
  Malaysia              119                  130                   5                                       4                             2008                                           2008                  2001 to 2013   2003 to 2011
  Mexico                1                    1                     11                                      3                             2007                                           1999                  1998 to 2006   Excluded
  Peru                  54                   44                    6                                       3                             2006                                           2006                  2002 to 2014   2004 to 2007
  South Africa          3328                 3207                  5                                       5                             2009                                           2009                  2000 to 2013   2002 to 2013
  Thailand              686                  595                   8                                       8                             2006                                           2006                  2000 to 2013   2002 to 2012
  Overall (IQR)         4405                 4182                  6 (2 to 10)                             6 (2 to 9)                    2009 (2006 to 2011)                            2009 (2006 to 2011)   1997 to 2014   2002 to 2013
  High‐income                                                                                                                                                                                                                
  Australia             1                    0                     11                                      ‐                             2000                                           ‐                     1999 to 1999   Excluded
  Austria               1                    0                     16                                      ‐                             2001                                           ‐                     2001 to 2001   Excluded
  Denmark               31                   17                    8                                       7                             2003                                           2003                  1997 to 2012   Excluded
  France                115                  92                    1                                       1                             2005                                           2004                  1996 to 2013   1997 to 2008
  Germany               11                   22                    6                                       9                             2004                                           2005                  1998 to 2011   Excluded
  Netherlands           114                  115                   3                                       4                             2004                                           2004                  1997 to 2013   1997 to 2012
  Spain                 181                  159                   2                                       2                             2005                                           2005                  1996 to 2013   1998 to 2011
  Switzerland           1                    0                     16                                      ‐                             1999                                           ‐                     1999 to 1999   Excluded
  United Kingdom        601                  590                   7                                       6                             2005                                           2004                  1996 to 2013   1997 to 2012
  United States         741                  681                   7                                       6                             1998                                           1998                  1995 to 2010   1996 to 2006
  Overall (IQR)         1797                 1676                  6 (2 to 10)                             6 (2 to 10)                   2002 (1998 to 2006)                            2001 (1998 to 2006)   1995 to 2013   1996 to 2012

cART, combination antiretroviral therapy; IQR, interquartile range.
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###### 

CD4 cell count and CD4% at the start of cART and the percentage of children starting cART with severe immunodeficiency by country income group. In the imputed analysis, 52,153 children were included and in the complete case analysis 34,363

                        Percentage of children missing both CD4 count and CD4% measurements   Median CD4 cell count at start of cART in cells/μL of children 5 years and older   Median CD4% at start of cART in cells/μL of children younger than 5 years   Percentage of children starting cART with severe immunodeficiency                                                                                                                           
  --------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------ ------------------ --------------- --------------- --------------- --------------- ----- ----- ----- -----
  Low‐income                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Benin                 15%                                                                   19%                                                                                161                                                                         146                                                                 159                146                20              24              15              17              67%   58%   65%   54%
  Burkina Faso          27%                                                                   28%                                                                                314                                                                         284                                                                 314                280                12              13              12              14              52%   54%   53%   54%
  Cambodia              4%                                                                    5%                                                                                 180                                                                         213                                                                 162                195                12              11              12              11              70%   68%   68%   63%
  Congo, DR             17%                                                                   18%                                                                                302                                                                         217                                                                 302                218                ‐               ‐               ‐               ‐               37%   46%   38%   46%
  Haiti                 9%                                                                    5%                                                                                 255                                                                         248                                                                 255                252                18              18              18              18              46%   48%   48%   49%
  Kenya                 19%                                                                   18%                                                                                281                                                                         277                                                                 281                278                15              14              16              15              45%   47%   46%   49%
  Malawi                76%                                                                   79%                                                                                249                                                                         262                                                                 249                259                16              14              15              14              46%   53%   47%   54%
  Mali                  8%                                                                    6%                                                                                 210                                                                         169                                                                 214                169                16              15              15              13              59%   62%   61%   66%
  Mozambique            44%                                                                   47%                                                                                369                                                                         427                                                                 368                402                8               16              14              14              35%   53%   59%   69%
  Rwanda                28%                                                                   26%                                                                                279                                                                         283                                                                 277                283                ‐               ‐               ‐               ‐               33%   33%   37%   36%
  Tanzania, UR          39%                                                                   40%                                                                                160                                                                         122                                                                 151                117                40              45              28              13              65%   67%   49%   67%
  Togo                  36%                                                                   34%                                                                                377                                                                         366                                                                 386                375                ‐               ‐               16              15              40%   38%   51%   49%
  Uganda                24%                                                                   25%                                                                                151                                                                         150                                                                 151                150                15              14              16              14              64%   68%   64%   68%
  Zimbabwe              29%                                                                   31%                                                                                233                                                                         217                                                                 231                214                15              14              15              14              45%   49%   48%   54%
  Overall (IQR)         30%                                                                   30%                                                                                254 (119 to 418)                                                            243 (94 to 411)                                                     253 (120 to 411)   244 (99 to 410)    15 (10 to 22)   14 (10 to 20)   16 (11 to 22)   14 (10 to 20)   46%   50%   48%   53%
  Lower middle‐income                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Cote d\'Ivoire        22%                                                                   25%                                                                                279                                                                         293                                                                 284                311                14              13              14              13              51%   56%   50%   52%
  Ghana                 29%                                                                   24%                                                                                257                                                                         237                                                                 257                231                ‐               ‐               12              14              46%   43%   57%   60%
  India                 7%                                                                    14%                                                                                227                                                                         193                                                                 227                193                10              14              10              14              48%   63%   48%   63%
  Indonesia             13%                                                                   10%                                                                                57                                                                          63                                                                  49                 63                 12              10              12              7               81%   82%   82%   83%
  Lesotho               31%                                                                   32%                                                                                270                                                                         262                                                                 256                251                22              16              19              16              44%   47%   46%   50%
  Senegal               37%                                                                   30%                                                                                221                                                                         264                                                                 213                267                16              14              14              14              49%   51%   56%   58%
  Vietnam               10%                                                                   11%                                                                                164                                                                         117                                                                 163                119                16              14              15              13              62%   67%   62%   67%
  Zambia                23%                                                                   21%                                                                                265                                                                         259                                                                 264                261                17              16              16              16              49%   52%   50%   54%
  Overall (IQR)         22%                                                                   21%                                                                                261 (120 to 447)                                                            254 (115 to 444)                                                    262 (121 to 447)   259 (116 to 449)   16 (11 to 23)   15 (10 to 21)   16 (11 to 22)   15 (10 to 21)   50%   54%   51%   55%
  Upper middle‐income                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Brazil                19%                                                                   15%                                                                                444                                                                         299                                                                 443                297                19              19              19              19              33%   40%   32%   42%
  Malaysia              20%                                                                   17%                                                                                77                                                                          177                                                                 77                 175                17              16              16              14              73%   64%   72%   65%
  Peru                  22%                                                                   23%                                                                                267                                                                         68                                                                  270                205                ‐               ‐               16              20              48%   80%   46%   52%
  South Africa          29%                                                                   30%                                                                                220                                                                         218                                                                 223                225                17              16              17              16              54%   56%   54%   55%
  Thailand              14%                                                                   13%                                                                                112                                                                         67                                                                  112                64                 14              13              13              13              64%   72%   64%   72%
  Overall (IQR)         26%                                                                   27%                                                                                193 (70 to 353)                                                             183 (46 to 342)                                                     200 (75 to 361)    196 (52 to 356)    17 (11 to 23)   16 (11 to 23)   17 (11 to 23)   15 (10 to 23)   56%   58%   55%   57%
  High‐income                                                                                                                                                                                                                                                                                                                                                                                                                                            
  France                9%                                                                    8%                                                                                 283                                                                         416                                                                 310                416                36              34              35              35              29%   28%   26%   27%
  Netherlands           18%                                                                   18%                                                                                310                                                                         320                                                                 310                320                24              18              22              19              36%   39%   32%   40%
  Spain                 21%                                                                   27%                                                                                323                                                                         389                                                                 286                368                29              25              29              26              35%   38%   32%   33%
  United Kingdom        17%                                                                   16%                                                                                272                                                                         253                                                                 270                251                20              17              20              17              39%   48%   40%   48%
  United States         1%                                                                    1%                                                                                 484                                                                         441                                                                 484                441                31              28              31              28              18%   24%   18%   24%
  Overall (IQR)         10%                                                                   11%                                                                                350 (206 to 608)                                                            342 (154 to 597)                                                    341 (196 to 590)   331 (152 to 590)   28 (17 to 38)   24 (14 to 33)   27 (17 to 37)   24 (14 to 33)   28%   35%   28%   35%

cART, combination antiretroviral therapy; IQR, interquartile range.
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3.2. Analysis of temporal trends in CD4 measurements {#jia225200-sec-0014}
----------------------------------------------------

Further analyses were based on 52,153 children, among whom CD4 measurements were imputed for 17,790 patients. (Table [S1](#jia225200-sup-0001){ref-type="supplementary-material"}). Figure [2](#jia225200-fig-0002){ref-type="fig"} shows modelled temporal trends in the prevalence of severe immunodeficiency at cART initiation. Figure [3](#jia225200-fig-0003){ref-type="fig"} shows corresponding trends in median CD4 counts (children aged ≥5 years) or CD4% (children \<5 years). In LIC, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% in 2004 to 42% in 2013. Corresponding figures were 67% to 46% (LMIC), 61% to 43% (UMIC) and 45% to 14% (HIC, 1996 to 2012). Of note, in LIC among children aged \<1 year, there was almost no decline in the proportion starting cART with severe immunodeficiency.

![**Severe immunodeficiency at the start of cART by age, sex and country income groups (colours)**\
Severe immunodeficiency was defined according to WHO as CD4% \<25% (age \<12 months), \<20% (12 to 35 months), \<15% (36 to 59 months) and CD4 count \<200 cells/μL or CD4% \<15% (≥5 years). Results from generalized additive mixed effects models based on 52,153 children after imputation of missing data. 95% CIs are shown as shaded areas. Vertical lines indicate the changes in WHO guidelines on when to start cART. Age groups are shown along the right edge. Note that no data available for the analysis for 2003 in LMIC and after 2012 for HIC; hence, the periods shown on the graph differ slightly by country income group. cART, combination antiretroviral therapy; WHO, World Health Organization; LMIC, lower middle‐income country; HIC, high‐income country.](JIA2-21-e25200-g002){#jia225200-fig-0002}

![**Median CD4 cell count in children aged 5 years or older and median CD4% in children below 5 years of age at the start of cART by age, sex and income group (colours)**\
Results from generalized additive mixed effects models based on 52,153 children after imputation of missing data. 95% CIs are shown as shaded areas. Vertical lines indicate the changes in WHO guidelines on when to start cART. Age groups are shown along the right edge. cART, combination antiretroviral therapy; WHO, World Health Organization.](JIA2-21-e25200-g003){#jia225200-fig-0003}

In LIC, the median CD4 cell count at cART initiation in children aged ≥5 years increased by 67% during 2004 to 2013, (162 to 271 cells/μL). Corresponding increases were 55% (151 to 234 cells/μL) (LMIC), 35% (164 to 222 cells/μL) (UMIC) and 144% (185 to 452 cells/μL) (HIC, 1996 to 2012). In children aged \<5 years, median CD4% increased during 2004 to 2013 from 11% to 17% in LIC, 10% to 16% in LMIC, 14% to 20% in UMIC and 22% to 29% in HIC (1996 to 2012) (Figure [3](#jia225200-fig-0003){ref-type="fig"}). Results of complete case analysis were similar (Figures [S2](#jia225200-sup-0001){ref-type="supplementary-material"} and [S3](#jia225200-sup-0001){ref-type="supplementary-material"}).

Temporal trends in median age at cART initiation varied among country income groups (Figure [S4](#jia225200-sup-0001){ref-type="supplementary-material"}). There was no clear trend in median age at cART initiation in LMIC, while there was a decrease from 2004 to 2013 in LIC (6.2 to 4.6 years) and an increase in UMIC (4.5 to 7.8 years) as well as HIC (2.1 (1996) to 7.4 years (2012)).

3.3. Influence of WHO guidelines on the proportion starting cART with advanced disease {#jia225200-sec-0015}
--------------------------------------------------------------------------------------

There was a significant decrease in the percentage of children starting cART with severe immunodeficiency in at least one period in all country income groups (Table [3](#jia225200-tbl-0003){ref-type="table"}A, Table [S2](#jia225200-sup-0001){ref-type="supplementary-material"}A). The annual decrease in the proportion of children with severe immunodeficiency at cART initiation between 2006 and 2009 was −3.0% (95% CI: −4.1 to −1.9%) (LIC), −2.1% (95% CI: −3.3 to −0.7%) (LMIC) and −2.7% (95% CI: −4.5 to −0.7%) (UMIC). The slope coefficients from the segmented regression model show that there was an acceleration in the rate of decrease during the period 2006 to 2009 in LIC, LMIC and UMIC, but no further significant change in the rate of decrease from 2010 to 2013 (Table [3](#jia225200-tbl-0003){ref-type="table"}B, Table [S2](#jia225200-sup-0001){ref-type="supplementary-material"}B).

###### 

Decline in percentage of children starting cART with severe immunodeficiency by calendar period, reflected by (A) average change in percentage per year within each WHO guideline period and (B) rate of decrease presented as estimated slope coefficient from the segmented regression analysis. This analysis was based on 52,153 patients after imputation of missing values

                                                                                                                 Low‐income                              Lower middle‐income                     Upper middle‐income                     High‐income
  -------------------------------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ------------------------------------
  A. Average change of % of children starting with severe immunodeficiency per year within the period (95% CI)                                                                                                                           
  2002 to 2005                                                                                                   1.6% (−2.1% to 5.7%)                    **6.6% (2.3% to 11.3%)**                2.2% (−0.7% to 5.1%)                    −1.6% (−4.8% to 1.5%)
  2006 to 2009                                                                                                   −**3.0% (**−**4.1% to** −**1.9%)**      −**2.1% (**−**3.3% to** −**0.7%)**      −**2.7% (**−**4.5% to** −**0.7%)**      −1.2% (−3.7% to 1.3%)
  2010 to 2013                                                                                                   −**2.1% (**−**3.4% to** −**0.8%)**      −**3.8% (**−**5.4% to** −**2.1%)**      −**2.7% (**−**4.9% to** −**0.3%)**      −**4.3% (**−**5.6% to** −**1.3%)**
  B. Estimated slope coefficient on the logit scale for the reference period (RP) and contrasts (95% CI)                                                                                                                                 
  2006 to 2009 (RP)                                                                                              −**0.122 (**−**0.171 to** −**0.076)**   −**0.088 (**−**0.147 to** −**0.030)**   −**0.108 (**−**0.187 to** −**0.030)**   −0.059 (−0.182 to 0.064)
  2002 to 2005 minus RP                                                                                          **0.190 (0.014 to 0.368)**              **0.373 (0.183 to 0.569)**              **0.198 (0.058 to 0.340)**              −0.012 (−0.215 to 0.199)
  2010 to 2013 minus RP                                                                                          0.039 (−0.026 to 0.103)                 −0.064 (−0.138 to 0.011)                −0.001 (−0.107 to 0.105)                −0.267 (−0.584 to 0.031)

*Notes:* In (A), negative values indicate reductions and positive values increases in the percentage of children starting cART with severe immunodeficiency; values can be considered significantly different from zero if the corresponding CI does not include zero (shown in bold). In (B), negative slopes for the reference period (2006 to 2009) indicate an accelerated rate of decrease, and slopes in other periods are compared with the reference period. Positive values indicate a slower rate of decrease and negative values a faster rate of decrease than the reference period. Slopes are significantly different from the reference period if the corresponding CI does not contain zero (shown in bold). cART, combination antiretroviral therapy; WHO, World Health Organization.
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4. Discussion {#jia225200-sec-0016}
=============

In our study of about 52,000 children from 32 countries, we found that since the 2006 and 2010 WHO Guidelines addressing paediatric cART eligibility, there have been annual reductions in the proportion of children starting cART with severe immunodeficiency in almost all country income groups. By 2013, less than half of children had severe immunodeficiency when starting cART in all country income groups. Nevertheless, considerable global inequity in advanced HIV disease at cART initiation remains; in 2013, \>40% of children in low‐ and middle‐income countries still started cART with severe immunodeficiency compared to \<20% in HIC.

4.1. Relationship with WHO Treatment Guidelines {#jia225200-sec-0017}
-----------------------------------------------

The goal of increasing paediatric cART coverage is one of the key reasons for the WHO 2015 recommendation of immediate cART irrespective of CD4 for all children [4](#jia225200-bib-0004){ref-type="ref"}. It is therefore encouraging that previous guideline revisions that expanded paediatric cART eligibility have been temporally associated with reduction in the proportion of children with advanced HIV disease at cART initiation. Nevertheless, except in HIC, more than 40% of children continued to start cART with severe immunodeficiency in 2013. This supports expanding immediate cART to all children, and indicates that WHO guideline changes alone are insufficient to achieve optimal treatment coverage. Ongoing and proactive engagement by WHO with ministries of health should focus on implementing paediatric testing and treatment guidelines.

Expansion of cART eligibility needs to be accompanied by efforts to ensure sufficient and sustainable access to HIV commodities as well as strengthened health systems, including trained health workers and infrastructure, which requires political will and adequate funding [33](#jia225200-bib-0033){ref-type="ref"}. Inequities in the proportions of children starting cART with severe immunodeficiency were not only seen between different country income groups, but also among countries in the same income group. For example, in LICs, the proportion of children starting cART with severe immunodeficiency ranged across countries from 33% to 69%. This may be partly due to the particular programmes in these countries that contributed to this analysis, and the years in which those programmes initiated the majority of children on cART. It is also possible that different levels of donor and national government funding and political will contributed to these differences.

It is somewhat surprising that there were no clear decreases in median age at cART start across all country income groups since eligibility for immediate cART irrespective of CD4 values applied initially to the youngest children (\<2 years) and only expanded to those \<5 years in 2013 (Figure [S4](#jia225200-sup-0001){ref-type="supplementary-material"}) [2](#jia225200-bib-0002){ref-type="ref"}, [3](#jia225200-bib-0003){ref-type="ref"}. However, interpreting trends in age at cART initiation is complex [21](#jia225200-bib-0021){ref-type="ref"}. The WHO guideline shifts towards universal treatment eligibility for progressively older groups of children have been accompanied by recommendations of more effective PMTCT, namely universal lifelong cART for all pregnant and breastfeeding women (so‐called "Option B+"). By 2013, the population of two‐ to five‐year olds eligible for immediate treatment would likely have decreased, both due to fewer new infections as well as some children already having started cART at less than two years of age following the implementation of 2010 guidelines. The median age at cART initiation thus depends on the effectiveness of PMTCT programmes in preventing new infant infections, capacity for EID and early cART, as well as the backlog of older children not yet on therapy [34](#jia225200-bib-0034){ref-type="ref"}, [35](#jia225200-bib-0035){ref-type="ref"}. There was a decrease in age at cART initiation in LIC, suggesting that the WHO 2010 guideline recommendation of universal cART for all children \<2 years may have had the greatest impact in the poorest countries, where EID capacity increased substantially in this period [36](#jia225200-bib-0036){ref-type="ref"}, [37](#jia225200-bib-0037){ref-type="ref"}, [38](#jia225200-bib-0038){ref-type="ref"}, [39](#jia225200-bib-0039){ref-type="ref"}. Nevertheless, there was little temporal improvement in the proportion of children \<1 year with severe immunosuppression, indicating that further improvements in EID and early cART access are urgently needed.

While there was an increase in overall age at cART initiation in UMIC, this may partly be due to effectiveness of PMTCT programmes preventing new infections. These countries nevertheless experienced the steepest decline in the proportion of infants with severe immunosuppression, indicating substantial progress in achieving cART initiation before the onset of advanced disease in infants. The overall increase in median age in both UMIC and HIC is likely due to reductions in new infant infections due to effective PMTCT, with a relative increase in the proportion of long‐term survivors initiating cART. Indeed, in Southern Africa, we have shown an increase in the proportions of children \<1 year and \>10 years old initiating cART [40](#jia225200-bib-0040){ref-type="ref"}. In Europe, many older patients presenting for testing and care may be immigrants, predominantly from sub‐Saharan Africa [41](#jia225200-bib-0041){ref-type="ref"}, [42](#jia225200-bib-0042){ref-type="ref"}, [43](#jia225200-bib-0043){ref-type="ref"}.

4.2. From improving paediatric cART access to improving paediatric HIV outcomes {#jia225200-sec-0018}
-------------------------------------------------------------------------------

CD4 at cART initiation is a useful indicator of responsiveness to WHO treatment initiation guidelines and indicates the extent to which we are successfully preventing advanced HIV disease through early cART initiation [44](#jia225200-bib-0044){ref-type="ref"}. Early cART initiation and retention are particularly critical in infants, as disease progression without cART is rapid and associated with high mortality. However, increasing CD4 at treatment start will only result in improved paediatric outcomes if those children are retained and adherent to effective treatment. There is a much‐needed emphasis on children in the UNAIDS 90:90:90 goals which focus not just on diagnosis and treatment access, but also aim for 90% retention on cART, with 90% viral suppression [44](#jia225200-bib-0044){ref-type="ref"}. Indeed, the WHO 2015 treatment guidelines highlight as a research gap the effect of early cART on retention and adherence [4](#jia225200-bib-0004){ref-type="ref"}. The IeDEA collaboration has previously found loss‐to‐follow‐up rates in children by 18 months after cART initiation ranging from 4.1% in Asia to 21.8% in West Africa [45](#jia225200-bib-0045){ref-type="ref"}. A recent analysis as part of an IeDEA‐WHO Collaboration found that children \<2 years of age and youth aged 15 to 24 years were least likely to be retained in care [46](#jia225200-bib-0046){ref-type="ref"}. Expanding paediatric cART therefore requires strategies not only to improve diagnosis and cART initiation, but also to optimize retention and support adherence across the paediatric and adolescent age spectrum. As more children are initiated on treatment at younger ages, better access to viral load monitoring to assess treatment effectiveness as well as paediatric‐friendly second‐ and third‐line drugs will become more important.

4.3. Strengths and limitations {#jia225200-sec-0019}
------------------------------

This analysis included a large number of children from many countries and all income group settings. It is one of the first analyses with substantial numbers of children that initiated cART after the WHO 2010 guidelines, allowing enough time to examine their effects. The inclusion of European data where, at least in some countries, there were sufficient numbers of children initiating cART to include data up to 2012, allows for comparison between all income settings after the 2006 and 2010 guideline revisions. A key limitation of our study is that we looked at the impact of WHO guidelines and not individual country guidelines on changes in CD4 at cART initiation. Although in some cases country guidelines pre‐date WHO guidelines, they more frequently lag behind WHO guidelines, which may explain the lack of a clearer effect of WHO guidelines on CD4 at cART start. Furthermore, in some country income groups, most data were from only one or two countries. Similarly, for some countries, data may have originated from a small number of programmes or from particular years. This may partly explain the diversity in findings within the same country income group, and our results may not be generalizable to the whole country or income group. However, to reflect reality as best as possible, we used a weighted analysis approach, with more weight assigned not only to more precise estimates obtained from countries contributing many observations to our data set but also dependent on the UNAIDS estimated number of children starting cART in a given country and year [31](#jia225200-bib-0031){ref-type="ref"}, so that countries with many children starting cART were adequately represented in our analysis. It is also possible that the facilities included in our analysis reflect better access to paediatric cART than occurs in the whole country or income group. However, almost all sites from LMICs in our cohorts are routine care facilities rather than dedicated research cohorts, and followed the relevant national cART guidelines. The routine nature of the data is reflected in the substantial proportions of missing CD4 data at cART initiation, with almost one third of patients missing a CD4 measurement in LIC. We conducted multiple imputation to minimize bias due to missing data. Results including the imputed values were very similar to those of complete case analyses. However, it is possible that there is residual bias. For example if children with poorer health were less likely to have CD4 measurements performed, this would violate the assumption of values "missing at random" [30](#jia225200-bib-0030){ref-type="ref"} and lead to an underestimation of the proportion of children starting cART with severe immunodeficiency.

5. Conclusions {#jia225200-sec-0020}
==============

The results of this study represent a milestone in efforts to increase paediatric cART access worldwide. We are almost halfway there. In 2012/2013, for the first time in all country income groups, approximately half of children initiating cART did not have severe immunodeficiency. This is at least partly attributable to WHO guidelines changes that expanded paediatric cART eligibility. Nevertheless, the persistence of disparities in cART access across income group settings are also reflected in our data showing that in 2013 there were still \>40% of children starting cART with severe immunosuppression in LMICs. The WHO 2016 guidelines provide an opportunity to expand paediatric cART access to infants, children and adolescents and encourage monitoring of the effect of the guidelines not only on immunological status at cART initiation, but also on retention and treatment effectiveness to comprehensively evaluate the effectiveness of paediatric cART programmes.
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**Appendix S1.** Supplementary material.

**Table S1.** Comparison of patients starting cART with and without CD4 cell count. Analysis of 44,480 patients included in multiple imputation and regression analyses

**Table S2.** Decline in percentage of children starting cART with severe immunodeficiency by calendar period, reflected by (A) average change in percentage per year within each WHO guideline period and (B) rate of decrease presented as estimated slope coefficient from the segmented regression analysis. This analysis was based on complete cases (34,363 children)

**Figure S1.** Flow chart of children included and excluded from analyses.

**Figure S2.** Severe immunodeficiency at the start of cART by age (rows), sex (columns) and country income groups (colours). Results from generalized additive mixed effects models based on 34,363 children with complete data. 95% CIs are shown as shaded areas.

**Figure S3.** Median CD4 cell count in children aged 5 years or older and median CD4% in children below 5 years of age at the start of cART by age (rows), sex (columns) and income group (colours). Results from generalized additive mixed effects models based on 34,363 children with complete data. 95% CIs are shown as shaded areas.

**Figure S4.** Median age in years at start of cART by income group. Analysis based on 52,153 patients.
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